Kazia Therapeutics LTD is a US-listed company in the biotechnology industry. Its financial year ends in June.
Loading chart…
Third-party market data · may be delayed
Under review: data-quality checks not passed.
Under review: data-quality checks not passed. We'll show the comparison once resolved.
Kazia Therapeutics LTD valuation: adjust assumptions and compare models →
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
Kazia Therapeutics LTD has little or no product revenue yet; it used $9m of cash in the twelve months. The diluted share count is up 107.8% on a year earlier, which dilutes existing holders. It passes 1 of our 2 financial-health checks.
Our model value for Kazia Therapeutics is under review, so past values are not shown until it is resolved.
Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.
Kazia Therapeutics LTD's trailing-twelve-month revenue fell 98.2% year on year, with a free-cash-flow margin of -31614.3%.
Current signal Free cash flow diverging from earnings: TTM free cash flow fell 37.0% while net income grew 23.6%: a 61pp divergence.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Loading chart…
Third-party market data · may be delayed
Company announcements, filed results and changes that matter to shareholders.
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
No analyst estimates are published for Kazia Therapeutics LTD: too few analysts cover it.
Source: SEC EDGAR filings. Retrieved November 1, 2026.
| Period | Revenue (TTM) |
|---|---|
| FY16 Q4 | $295.9K |
| FY17 Q4 | $187.9K |
| FY18 Q4 | $92.3K |
| FY21 Q4 | $11.3M |
| FY22 Q4 | $0 |
| FY23 Q4 | $0 |
| FY24 Q4 | $1.5M |
| FY25 Q4 | $27.2K |
Source: SEC EDGAR filings. Retrieved November 1, 2026.
| Period | Revenue growth, TTM YoY |
|---|---|
| FY17 Q4 | -36.5% |
| FY18 Q4 | -50.9% |
| FY22 Q4 | -100.0% |
| FY25 Q4 | -98.2% |
Source: SEC EDGAR filings. Retrieved November 1, 2026.
| Period | FCF margin (TTM) |
|---|---|
| FY16 Q4 | -3079.3% |
| FY17 Q4 | -4597.2% |
| FY18 Q4 | -7277.3% |
| FY21 Q4 | -60.0% |
| FY24 Q4 | -415.1% |
| FY25 Q4 | -31614.3% |
| Fiscal year | 2016 Jun 2016 | 2017 Jun 2017 | 2018 Jun 2018 | 2021 Jun 2021 | 2022 Jun 2022 | 2023 Jun 2023 | 2024 Jun 2024 | 2025 Jun 2025 |
|---|---|---|---|---|---|---|---|---|
| Income | ||||||||
| Revenue | 0 | 0 | 0 | 11 | 0 | 0 | 2 | 0 |
| Net income | −9 | −8 | −5 | −6 | −18 | −14 | −18 | −13 |
| Diluted EPS | — | — | — | −$13.37 | −$34.25 | −$18.90 | −$16.65 | −$12.24 |
| Growth (year on year) | ||||||||
| Revenue | — | −36.5% | −50.9% | +>999% | −100.0% | — | — | −98.2% |
| Margins | ||||||||
| Net margin | <−999% | <−999% | <−999% | −55.5% | — | — | <−999% | <−999% |
| Free-cash-flow margin | <−999% | <−999% | <−999% | −60.0% | — | — | −415.1% | <−999% |
| Cash flow | ||||||||
| Cash from operations | −9 | −9 | −7 | −7 | −17 | −10 | −6 | −9 |
| Capital spending | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | −9 | −9 | −7 | −7 | −17 | −10 | −6 | −9 |
| Stock-based pay | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Free cash flow after stock pay | −9 | −9 | −7 | −7 | −18 | −11 | −7 | −9 |
| Balance sheet | ||||||||
| Cash | 25 | 11 | 4 | 21 | 5 | 3 | 1 | 3 |
| Total debt | 0 | 0 | 0 | — | 1 | 1 | 0 | 0 |
| Net debt (negative = net cash) | −25 | −11 | −4 | −21 | −4 | −2 | −1 | −3 |
| Diluted shares | — | — | — | — | — | — | 1m | 1m |
| Last 12 months unless stated | KZIA | LYEL | AIM | IBIO | LSTA | CLDX | Median |
|---|---|---|---|---|---|---|---|
| Revenue, last 12 months | $27211 | $27000 | $95000 | $100000 | $100000 | $158000 | $55m |
| Revenue growth, last 12 months | −98.2% | −55.0% | −21.5% | −75.0% | −90.7% | −97.3% | 12.2% |
| Revenue growth, 3-year average | — | −91.8% | −17.3% | −62.4% | — | −63.5% | 13.7% |
| Revenue growth, latest quarter | — | −50.0% | 4.0% | −100.0% | −100.0% | −97.0% | 10.2% |
| Gross margin | — | — | −968.5% | 59.9% | 7.7% | — | 82.9% |
| Operating margin | — | <−999% | <−999% | <−999% | <−999% | <−999% | −189.4% |
| Operating margin, 3-year average | — | <−999% | <−999% | <−999% | <−999% | <−999% | −363.5% |
| Net margin | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | −172.8% |
| Cash from operations / revenue | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | −168.8% |
| Free-cash-flow margin | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | −168.1% |
| Free-cash-flow margin, 3-year average | — | <−999% | <−999% | <−999% | <−999% | <−999% | −310.0% |
| Stock pay / revenue | >999% | >999% | 0.0% | >999% | >999% | >999% | 20.7% |
| Change in share count | 107.8% | — | 49.8% | 13.9% | 5.1% | 4.7% | 8.3% |
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Boxer Capital Management, LLC | $7.9M | 560K | 15.5% | New |
| Flputnam Investment Management Co | $5.8M | 415K | 11.5% | ▲ 191.3% |
| Bleichroeder LP | $5.6M | 400K | 11.1% | 0.0% |
| Ikarian Capital, LLC | $5.6M | 396K | 11.0% | New |
| Dauntless Investment Group, LLC | $5M | 354K | 9.8% | ▲ 343.7% |
| Stonepine Capital Management, LLC | $4.9M | 345K | 9.6% | 0.0% |
| Point72 Asset Management, L.P. | $2.3M | 200K | 4.5% | ▲ 0.2% |
| Ensign Peak Advisors, Inc | $1.6M | 111K | 3.1% | New |
| Millennium Management LLC | $1.4M | 101K | 2.8% | New |
| UBS Group AG | $1.1M | 81K | 2.3% | ▲ 482.0% |
| J. Goldman & Co LP | $964,353 | 68K | 1.9% | New |
| ADAR1 Capital Management, LLC | $866,624 | 62K | 1.7% | New |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Kazia Therapeutics LTD's complete shareholder register. Values are as reported by the filers .
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
New research on the companies we cover arrives in the weekly email. Free, one email a week.
